Alpha-Galactosidase для Bloating and Intestinal Gas
B Доказательства По меньшей мере одно рандомизированное исследование подтверждает это, с в целом согласованными результатами.Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dalpha\u002Dgalactosidase\u0026condition\u003Dbloating\u002Dand\u002Dgas';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
Итог
Reduces gas symptoms from high-fiber foods containing raffinose/stachyose by 50-70%. Beano (alpha-galactosidase 300 GalU) is the most studied formulation.
Key Study Findings
Review
Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review.
Dose: None
или: None
Outcome: None
Эффект: None
None
Популяция: None
Randomized Controlled Trial
Double-blind
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal …
Dose: 1200 G
или: placebo
Outcome: every 30 min during 7
Эффект: None
None
Популяция: patients with ibs after three standardized
Other
n=17
FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument.
Dose: None
или: no treatment
Outcome: None
Эффект: None
None
Популяция: fabry disease but are often nonspecific
Randomized Controlled Trial
n=31
2.0 weeks
Double-blind
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Dose: 300 GALU or 150 GALU
или: Placebo (glucose)
Outcome: GI symptom severity on VAS
Эффект: None
pP0.006
Популяция: IBS patients (Rome III, H2 producers)
Randomized Controlled Trial
n=125
4 weeks
Double-blind
Does oral α-galactosidase relieve irritable bowel symptoms?
Dose: alpha-galactosidase 600 GalU per meal
или: placebo
Outcome: overall IBS symptom relief
Эффект: no significant difference vs placebo
>0.05
Популяция: IBS patients
Case Reports
A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha …
Dose: 3.7nmol/mL/h
или: None
Outcome: None
Эффект: None
None
Популяция: patients
Key Statistics
4
Исследования
300
Участники
↑
Positive
B
Оценка
Referenced Papers
International journal of …
2021
16 цитирований
Quality of life …
2021
14 цитирований
Neurogastroenterology and motility
2021
4 цитирований
The American journal …
2018
49 цитирований
Scandinavian journal of …
2016
17 цитирований
Clinical biochemistry
2015
18 цитирований
BMC gastroenterology
2013
12 цитирований
Digestive diseases and …
2007
45 цитирований
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Other
Molecular genetics and …
2005
84 цитирований
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Часто используемые дозировки
- general:
- 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods
- standardbeanodose:
- 300 GalU (2-3 tablets) with first bite of problem food
Верхний предел: No established upper limit; adjust per meal as needed
Дозировки, изученные в исследованиях
| Дозировка | Длительность | Эффект | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| 1200 G | -- | Neutral | -- |
| None | -- | Positive | 17 |
| 300 GALU or 150 GALU | 2.0 weeks | Positive | 31 |
| alpha-galactosidase 600 GalU per meal | 4 weeks | Neutral | 125 |
| 3.7nmol/mL/h | -- | Mixed | -- |
| None | 2 weeks | Positive | -- |
| 300 or 1200 GalU | -- | Positive | 8 |
Лучшее время приёма: With the first bite of gas-producing food
Safety & Side Effects
Зарегистрированные побочные эффекты
- ⚠ Generally very well-tolerated
- ⚠ Rare allergic reactions to mold-derived enzyme (Aspergillus source)
- ⚠ May cause mild GI discomfort in rare cases
Известные взаимодействия
- ● Acarbose (alpha-galactosidase may counteract the blood sugar-lowering mechanism of acarbose; contraindicated for concurrent use)
- ● Miglitol (similar mechanism conflict as acarbose)
Допустимый верхний уровень потребления: No established upper limit; adjust per meal as needed
Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.
Frequently Asked Questions
Does Alpha-Galactosidase help with Bloating and Intestinal Gas?
Based on 4 studies with 300 participants, there is moderate evidence from clinical studies that Alpha-Galactosidase may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Alpha-Galactosidase should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 150-300 GalU (alpha-galactosidase units) per serving of gas-producing foods. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Alpha-Galactosidase?
Reported side effects may include Generally very well-tolerated, Rare allergic reactions to mold-derived enzyme (Aspergillus source), May cause mild GI discomfort in rare cases. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Alpha-Galactosidase and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.
Related Evidence
Другие ингредиенты для Bloating and Intestinal Gas
Alpha-Galactosidase для других состояний
References
- [1] Fabio Caputo et al.. Int J Environ Res Public Health. 2021. Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. doi:10.3390/ijerph18063320 PubMed
- [2] Alan L Shields et al.. Qual Life Res. 2021. FABry Disease Patient-Reported Outcome-GastroIntestinal (FABPRO-GI): A new Fabry disease-specific gastrointestinal outcomes instrument. doi:10.1007/s11136-021-02847-9 PubMed
- [3] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [4] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [5] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [6] Antonino Tuttolomondo et al.. Clin Biochem. 2015. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene. doi:10.1016/j.clinbiochem.2014.09.018 PubMed
- [7] Giovanni Di Nardo et al.. BMC Gastroenterol. 2013. Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial. doi:10.1186/1471-230X-13-142 PubMed
- [8] Michele Di Stefano et al.. Dig Dis Sci. 2007. The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. doi:10.1007/s10620-006-9296-9 PubMed
- [9] Maryam Banikazemi et al.. Mol Genet Metab. 2005. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. doi:10.1016/j.ymgme.2005.04.009 PubMed
- [10] T G Ganiats et al.. J Fam Pract. 1994. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. PubMed
Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.